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AbstrAct
Objectives To develop and validate a tool to predict 
the risk of an older adult experiencing medication-related 
harm (MRH) requiring healthcare use following hospital 
discharge.
Design, setting, participants Multicentre, prospective 
cohort study recruiting older adults (≥65 years) 
discharged from five UK teaching hospitals between 
2013 and 2015.
Primary outcome measure Participants were 
followed up for 8 weeks in the community by senior 
pharmacists to identify MRH (adverse drug reactions, 
harm from non-adherence, harm from medication 
error). Three data sources provided MRH and 
healthcare use information: hospital readmissions, 
primary care use, participant telephone interview. 
Candidate variables for prognostic modelling were 
selected using two systematic reviews, the views of 
patients with MRH and an expert panel of clinicians. 
Multivariable logistic regression with backward 
elimination, based on the Akaike Information Criterion, 
was used to develop the PRIME tool. The tool was 
internally validated.
Results 1116 out of 1280 recruited participants 
completed follow-up (87%). Uncertain MRH cases 
(’possible’ and ’probable’) were excluded, leaving a 
tool derivation cohort of 818. 119 (15%) participants 
experienced ’definite’ MRH requiring healthcare use 
and 699 participants did not. Modelling resulted in 
a prediction tool with eight variables measured at 
hospital discharge: age, gender, antiplatelet drug, 
sodium level, antidiabetic drug, past adverse drug 
reaction, number of medicines, living alone. The 
tool’s discrimination C-statistic was 0.69 (0.66 after 
validation) and showed good calibration. Decision 
curve analysis demonstrated the potential value of the 
tool to guide clinical decision making compared with 
alternative approaches.
Conclusions The PRIME tool could be used to 
identify older patients at high risk of MRH requiring 
healthcare use following hospital discharge. Prior to 
clinical use we recommend the tool’s evaluation in 
other settings.
bAckground
Reducing the burden of serious and avoid-
able medication-related harm (MRH) 
by 50% by 2022 is WHO’s third global 
patient safety challenge.1 Transitions 
of care, particularly following hospital 
discharge,2 present a heightened risk 
and addressing this is a priority.3 Medi-
cation-related harm includes harm from 
adverse drug reactions (ADR), non-adher-
ence and medication errors.2
Older adults are especially vulnerable 
to experience MRH due to multimor-
bidity and polypharmacy,4 age-related 
changes in pharmacokinetics and phar-
macodynamics5 and adherence prob-
lems.6 Patients and carers identify the care 
transition around hospital discharge as a 
unique, high-risk period for the occur-
rence of MRH.7–9 Contributory factors 
include deconditioning during hospi-
talisation, ongoing recovery from acute 
illness,10 inaccuracies in medicines recon-
ciliation,11 insufficient patient education 
of medicines use12 and poor communi-
cation between secondary and primary 
care.13 14 A systematic review of MRH 
in older adults found that between 17% 
and 51% of patients experience MRH 
within 30 days of hospital discharge.2 In 
the UK, 28% of older adults (≥65 years) 
use health services due to MRH within 
the 8 weeks following hospital discharge, 
at a cost of £400 million (US$530 million) 
to the National Health Service (NHS) 
annually.15
Current strategies to address MRH 
during transitions of care include medi-
cines review incorporating a patient-cen-
tred approach to deprescribing16 17 and the 
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improvement of information transfer through medi-
cines reconciliation.18 Risk stratification using predic-
tion tools is recognised as one solution to enhance 
the cost-effectiveness of interventions by identifying 
patients likely to derive greatest benefit.19 20 Individual 
risk prediction can inform clinical decision making 
and support patient participation in their healthcare. 
Risk prediction tools such as the Framingham21 or 
QRISK22 tools for estimating cardiovascular risk have 
transformed the provision of healthcare.
Currently, no tools are available to target interven-
tion to patients at high risk of MRH in the commu-
nity following hospital discharge.23 Relying on clinical 
judgement alone is poorly predictive.24 A key recom-
mendation in a position statement from the Interna-
tional Group for Reducing Inappropriate Medication 
Use and Polypharmacy is to ‘develop tools that can 
aid the detection and management of drug adverse 
effects’.25
The aim of our study was to develop and validate a 
risk prediction tool to identify older patients at high 
risk of MRH requiring healthcare use within 8 weeks 
following hospital discharge.
Methods
design, setting and participants
The risk prediction tool reported in this paper was 
developed using data from a multicentre, prospective 
cohort study; Prospective study to develop a model 
to stratify the RIsk of Medication-related harm in 
hospitalised Elderly patients (PRIME).15 26 Detailed 
methods are in the published protocol.26 This study is 
reported in accordance with the transparent reporting 
of a multivariable prediction model for individual 
prognosis or diagnosis (TRIPOD) statement.27
Research nurses recruited inpatients (age ≥65 years) 
close to discharge from medical wards, between 2013 
and 2015, in five NHS teaching hospitals in England. 
Patients were excluded if they were terminally ill, if 
they lacked capacity with no nominated consultee or if 
they were transferred to other acute healthcare units.
baseline data collection
Research nurses collected baseline information from 
consenting patients using medical records and patient 
interview, including demographic, clinical and social 
data.
outcome definition
The risk prediction model was developed to predict 
MRH requiring healthcare within 8 weeks of hospital 
discharge. MRH was defined as an ADR or harm arising 
from non-adherence. Non-adherence was defined as 
failure to use medicines as the prescriber intended. 
Harm arising from medication error was included 
where reported. Intentional overdose was excluded. 
Asymptomatic derangements in blood markers were 
not included as MRH. This is a modified version of 
the definition by Strand et al.28
Healthcare use included primary, secondary or 
tertiary consultations related to MRH. Senior, research 
pharmacists followed participants for 8 weeks to deter-
mine MRH occurrence. An 8-week observation period 
was chosen as previous research outside of the UK 
had found this is a reasonable timeframe to capture 
most postdischarge MRH.29–31 Classification of MRH 
events was completed using the validated Naranjo 
algorithm as ‘possible’, ‘probable’ or ‘definite’.32–35 
Where an event was not suspected, this was classified 
as ‘doubtful’. To eliminate uncertainty and strengthen 
the external validity of the model, any events that were 
possible or probable were excluded. Only events that 
required healthcare use were included as an objective 
threshold for MRH severity.
Mrh and healthcare use assessment
Pharmacists identified MRH and healthcare use (acci-
dent and emergency department attendance, hospital 
admission, outpatient clinics, general practitioner (GP) 
in-person or telephone consultations and out-of-hours 
care) from three sources: (1) participant/carer tele-
phone interview at 8 weeks using a structured ques-
tionnaire, (2) GP records and (3) prospective review 
of hospital readmissions with the admitting medical 
consultant.
The Naranjo Algorithm35 was used to assess ADR 
causality in conjunction with the British National 
Formulary and Summary of Product Characteristics. 
Clinical judgement supported by a validated question-
naire36 and prescription order data were used to deter-
mine if non-adherence had contributed to MRH.
Two senior study pharmacists provided case-based 
training to all other pharmacists. Additionally, cross-
site case discussions were held to ensure standardisa-
tion of MRH assessments.
An end point committee independent from data 
collection, consisting of a professor of geriatrics, 
professor of clinical pharmacy and two consultant 
geriatricians reviewed, scrutinised and verified MRH 
cases.
selection of candidate predictors
Candidate variables for the PRIME tool were prospec-
tively selected by (1) two systematic reviews exploring 
previous MRH risk prediction tools, and, the epidemi-
ology of MRH postdischarge,2 23 (2) three round-table 
expert meetings to identify candidate predictors, prior 
to any data analysis, based on clinical relevance and 
practicality of routine measurement (including two 
professors of geriatrics, two consultant geriatricians, 
one professor of pharmacy, one hospital chief phar-
macist, one pharmacy research fellow and one geriat-
rics research fellow), (3) a qualitative study to identify 
MRH risk factors from the patient and carer perspec-
tive.37 At this initial stage no upper limit was placed on 
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the number of candidate variables.26 38 All candidate 
variables were selected based on clinical relevance and 
not using univariable analysis to avoid the possibility 
of variable inclusion by statistical chance.39 40 Once the 
number of MRH events in the study was known, the 
number of variables was reduced for model develop-
ment recognising 10 events per variable by Peduzzi et 
al as a rough indicator.38 However, the use of this ‘rule 
of thumb’ is not universally advocated.41 42
sample size
The study was adequately powered based on a calcu-
lation using the nomogram designed by Carley et al43 
and based on the work of Buderer et al.44 A sample 
size calculation was performed to achieve a sensitivity 
of 80% with a 95% CI width of 5% and based on an 
MRH prevalence rate of 30% (see online supplemen-
tary file for additional detail).
Missing data
Under a missing at random assumption, we imputed 
data on all variables with missing data; estimated 
glomerular filtration rate, hand grip strength, past 
ADR and living alone postdischarge. These values 
were replaced using Multiple Imputation by Chained 
Equations.45 For each variable 10 imputed datasets 
were created and Rubin’s rule was used to obtain an 
overall estimate.45 See online supplementary file for 
additional detail.
statistical analysis
All statistical analyses were conducted in Stata V.14 
(StataCorp, College Station, Texas, USA).
Model development
The primary outcome was whether a person experi-
enced MRH requiring healthcare use; a binary vari-
able. Backward elimination, based on the Akaike Infor-
mation Criterion (AIC), excluded variables that were 
not contributing sufficient predictive information in 
the multivariable logistic regression model46 (the AIC 
is a predictive metric that equates to the elimination 
of variables with p≥0.157). The AIC was chosen as 
the selection procedure as it balances the risk of over-
fitting a model to the derivation data and introducing 
misspecification error from trimming potentially 
meaningful variables, while penalising the inclusion 
of redundant variables contributing little predictive 
information to generate a parsimonious model.47 Two 
variables (age and sodium level) were centred on their 
mean values to make the interpretation of the inter-
cept easier and meaningful. In the model equation, 
the intercept can be interpreted as the predicted risk 
of MRH if all the continuous explanatory variables 
are set to 0 (and the categorical variables held at their 
baseline values), a value which is infeasible for contin-
uous variables such as age and sodium level. Therefore 
by centring these two variables, the intercept in the 
model equation would indicate the predicted risk of 
MRH with plausible values for age and sodium level. 
Two-way interactions between pairs of variables were 
tested and no significant interactions were found 
between them in their relationship with MRH.
A final model of eight predictors was obtained 
after backward elimination and a risk equation for 
predicting the log odds of MRH was formed by 
summing the products of the estimated β-coefficients 
(obtained from fitting the multivariable logistic regres-
sion model) and their corresponding observed predic-
tors, plus the intercept.
All the predictors were assessed for collinearity by 
calculating the variance inflation factor (VIF) to iden-
tify whether variances of the estimated coefficients 
were inflated.48
Evaluating model performance
The performance of the model was evaluated by its 
discrimination (area under the receiver operating char-
acteristic curve) and calibration (calibration slope and 
Hosmer-Lemeshow goodness-of-fit statistic).49
Bootstrap correction of model optimism and validation
Bootstrap is a model validation approach that is 
recommended when an external cohort of patients is 
unavailable to estimate the performance of the predic-
tion model.50–53 Bootstrap is a resampling method that 
is used to randomly generate data (data for subsets of 
patients) from the original sample with replacement 
(patients can be selected multiple times). The boot-
strap sample is the same size as the original sample 
(n=818). One hundred samples of the derivation data 
were bootstrapped, and, in each sample a prediction 
model was developed and used to compute an estimate 
of model optimism (see online supplementary file for 
additional detail).
Assessment of potential clinical usefulness
A net benefit approach using decision curve analysis 
was conducted to explore the potential clinical utility 
of the PRIME tool. This type of analysis measures the 
benefits and harms (in terms of true positives and false 
positives) of using the tool to guide intervention,54 that 
is, in the current context, intervention to avoid MRH. 
A decision analytic curve can compare the net benefit 
of using this new approach with existing approaches 
to guide intervention, for example, polypharmacy,16 17 
or an approach of treating all people of a particular 
risk threshold, or alternatively treating none. The 
‘threshold’ risk at which a clinician would decide to 
intervene is subjective and should incorporate patient 
preferences. Furthermore, the threshold will depend 
on the time and cost resource, invasiveness, effective-
ness and harms of the intervention.54 55 However, a 
reasonable range of threshold probabilities in the 
context of intervening on the risk of serious MRH was 
considered to be 5%–25%. This range reflects expert 
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Table 1 Baseline sample characteristics
Key characteristics,
n (%) unless otherwise stated No MRH (n=699)
MRH (possible, probable, 
definite) (n=413)
MRH definite requiring 
healthcare (n=119)
Age, mean (SD), years 80.9 (7.9) 81.7 (7.4) 82.6 (6.5)
Female* 383 (54.8) 268 (64.9) 81 (68.1)
Length of hospital stay, median (IQR), days 6 (3–13) 8 (4–14) 7 (3–14)
Charlson Comorbidity Index
  0–1 342 (48.9) 198 (47.9) 56 (47.1)
  ≥2 357 (51.1) 215 (52.1) 63 (52.9)
  Renal impairment† (eGFR <60) 260 (40.0) 170 (44.4) 59 (52.7)
Barthel score*, median (IQR) 18 (13–20) 17 (13–19) 17 (13–19)
Hand grip‡, median (IQR), kg
  Female 13.5 (10.0–18.3) 14.0 (10.0–18.0) 14.0 (10.0–18.0)
  Male 24.0 (19.0–31.0) 24.0 (17.8–31.0) 25.0 (18.5–30.0)
Number of medicines*, mean (SD) 8.9 (4.1) 10.0 (4.0) 10.4 (4.1)
Number of new medicines, mean (SD)* 3.1 (2.3) 3.5 (2.3) 3.4 (2.2)
  Past adverse drug reaction *§ 202 (29.1) 145 (35.4) 50 (42.4)
  Medication compliance aid
  (eg, dosette box)
224 (32.0) 146 (35.4) 50 (42.0)
  Living alone after discharge*¶ 322 (46.2) 228 (55.5) 69 (58.0)
*Significant difference between ‘MRH’ and ‘no MRH’ groups: female, p=0.001; Barthel score, p=0.012; number of medicines, p<0.001; past adverse 
drug reaction, p=0.037; living alone after discharge, p=0.003.
†Information not available for 79 participants.
‡Information not available for 117 participants.
§Information not available for 9 participants.
¶Information not available for 4 participants.
eGFR, estimated glomerular filtration rate mL/min/1.73 m2; MRH, medication-related harm.
consensus opinion of the multidisciplinary PRIME 
study coordinating team. The assumption here that 
it would be surprising if a patient had <5% risk of 
serious MRH and a decision was made to intervene, 
that is, an acceptance of intervening on 19 patients 
unnecessarily to avoid one patient experiencing MRH. 
Likewise, if a patient has >25% (one in four) chance 
of experiencing serious MRH it would be a surprising 
decision to take no action to mitigate this risk.
results
Participant characteristics
A total of 1280 older adults were recruited at hospital 
discharge for 8-week follow-up. Seventeen partici-
pants died without follow-up (1.3%), 147 participants 
(11.5%) were lost to follow-up because they were 
uncontactable and GP records were unavailable (see 
online supplementary file for further detail and partic-
ipant flow chart). One hundred nineteen participants 
experienced ‘definite’ MRH requiring healthcare use 
within 8 weeks following hospital discharge (an inci-
dence of 107 participants per 1000 discharged). The 
model derivation cohort included 818 participants 
with either ‘definite’ MRH requiring healthcare use 
or no MRH requiring healthcare use (table 1). The 
‘possible’ and ‘probable’ cases of MRH, as well as 
‘definite’ cases that did not require healthcare use were 
excluded.
Model development and performance
Twenty-five candidate variables were initially iden-
tified based on clinical judgement, existing literature 
and qualitative work with patients and carers. Three 
of the 25 variables (albumin level, C reactive protein, 
white cell count) were excluded due to substantial 
missing data (>20%). Two variables (change in accom-
modation after discharge and hepatic impairment) 
were excluded due to insufficient prevalence in the 
cohort (<10%). One variable (cardiovascular drug on 
discharge) was excluded due to saturated prevalence in 
the cohort (>80%). The remaining 19 variables were 
taken forward for potential inclusion in the final multi-
variable analysis, and 12 predictor combinations were 
trialled to obtain a parsimonious model with optimal 
performance and stability (broadly adhering to the 10 
events-per-variable ratio rule of thumb38 to reduce 
model performance bias56). Models were examined for 
evidence of multicollinearity, and where demonstrated 
the variable contributing the least predictive value 
was excluded. The iterative procedure resulted in the 
exclusion of a further seven variables (regular falls, 
Barthel score, addition of a new drug, opiate drug, 
anticoagulant drug, abbreviated mental test score, 
depression on screening). The 12 predictors included 
in a final multivariable model to generate the PRIME 
tool are shown in table 2 (see online supplementary 
file for summary of excluded variables).
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Table 2 Selected candidate predictors to derive the risk prediction model
Variable Data source and measurement Prevalence*
Unadjusted 
OR (95% CI) on 
univariable analysis
Adjusted OR (95% CI) multivariable 
regression based on backwards 
elimination based on Akaike 
Information Criterion (p>0.157)
β-Coefficients 
of variables 
included in 
model
P value in 
multivariable 
analysis
Age (years) Self-report and medical records 81.2 1.03 (1.00 to 1.06) 1.03 (1.00 to 1.05) 0.025 0.078
Gender (reference female) Self-report and medical records 43.3 (male)
56.7 (female)
0.57 (0.38 to 0.86) 0.67 (0.43 to 1.04) −0.398 0.075
Past ADR† Self-report and medical records 31.1% 1.79 (1.20 to 2.67) 1.61 (1.06 to 2.45) 0.477 0.026
Antiplatelet drug Discharge summary and medical 
records. Drugs coded B01AC on WHO-
ATC system
43.3% 1.78 (1.20 to 2.63) 1.67 (1.11 to 2.53) 0.515 0.014
Antidiabetic drug Discharge summary and medical 
records. Drugs coded A10A or A10B on 
WHO-ATC system
19.7% 1.89 (1.22 to 2.94) 1.81 (1.12 to 2.91) 0.591 0.016
Living alone† Self-report and medical records 47.9% 1.61 (1.08 to 2.38) 1.49 (0.98 to 2.27) 0.397 0.064
Sodium level (mmol/L) Last recorded inpatient biochemistry 
prior to discharge
137 0.97 (0.93 to 1.01) 0.96 (0.92 to 1.00) −0.042 0.069
Number of medicines Discharge summary and medical 
records. Total number of medicines at 
discharge
9 1.08 (1.04 to 1.13) 1.06 (1.00 to 1.11) 0.056 0.033
Hand grip strength (kg)† Southampton Protocol for Adult Grip 
strength Measurement using the 
JAMAR Hydraulic Hand Dynamometer93
25.6 (male)
14.3 (female)
0.98 (0.96 to 1.00) Eliminated from model (p>0.157) N/A 0.911
Medication compliance aid Multicompartment compliance aid on 
discharge
33.5% 1.54 (1.03 to 2.29) Eliminated from model (p>0.157) N/A 0.302
Renal impairment (eGFR 
<60 mL/min/1.73 m2)†
Last recorded inpatient biochemistry 
prior to discharge
41.9% 1.67 (1.13 to 2.47) Eliminated from model (p>0.157) N/A 0.216
Charlson Comorbidity Index Discharge summary and medical 
records
Total number of diseases defined by 
Charlson Comorbidity Index94
48.7% (<2)
51.3% (≥2)
1.12 (0.95 to 1.31) Eliminated from model (p>0.157) N/A 0.403
Past ADR was defined as any adverse drug reaction documented in the medical records and confirmed, where possible, during the process of medicines reconciliation.
*Percentage of patients for categorical predictor or average value for continuous predictor.
†Incomplete data for predictors; renal impairment (n=56) hand grip strength (n=100), past ADR (n=7), sodium level (n=4), lives alone (n=2).
ADR, adverse drug reaction; eGFR, estimated glomerular filtration rate; N/A, not available.
Backward elimination using the AIC (equating to 
p=0.157)46 resulted in a final risk prediction model 
of eight variables: age, gender (female=0), antiplatelet 
drug (antiplatelet on discharge=1), sodium level, anti-
diabetic drug (antidiabetic on discharge=1), history of 
ADR (past ADR=1), number of discharge medicines 
and living alone (living alone postdischarge=1). The 
final model equation along with case examples to illus-
trate use of the prediction tool is shown in figure 1.
The linear relationship between continuous predic-
tors (modelled on their continuous scales) and the 
log-odds of the outcome variable was assessed by 
the use of multivariable fractional polynomials. A 
Wald test showed that there was a linear relationship 
between the continuous variables and the log-odds of 
the outcome. No multicollinearity was demonstrated 
in this model (mean VIF=1.07). The apparent discrim-
ination of the model was AUC 0.69 (95% CI 0.64 to 
0.74) (figure 2). For comparison, the number of medi-
cines alone discriminated between higher and lower 
risk patients with AUC 0.61 (95% CI 0.55 to 0.66). A 
sensitivity analysis found a poorer model discrimina-
tion if ‘possible’ and ‘probable’ MRH were categorised 
with ‘definite’ MRH (C-statistic 0.64, 95% CI 0.60 to 
0.67), or if ‘probable’ events were grouped with ‘defi-
nite’ MRH (C-statistic 0.65, 95% CI 0.61 to 0.69).
The optimism of the model’s discriminatory perfor-
mance was 0.028, calculated as the average difference 
between model discrimination in the bootstrap sample 
and the discrimination of the bootstrap model in the 
original sample over 100 bootstrap iterations. The 
optimism adjusted model discrimination is AUC 0.66 
(95% CI 0.61 to 0.71).
The calibration, that is, the level of agreement 
between predicted and observed risk probabilities was 
good (see online supplementary file for calibration 
plot). The Hosmer-Lemeshow goodness-of-fit statistic 
was 5.47, with 8 df, p=0.71 indicating no evidence 
of statistically significant difference between the 
observed and expected values. A uniform shrinkage 
factor of 0.85, derived from the average of the cali-
bration slopes of the bootstrap iterations, was applied 
to predictor coefficients to adjust the risk prediction 
model for optimism. Figure 3 shows the results of 
the decision curve analysis, which demonstrates the 
superior net benefit that use of the PRIME tool offers 
compared with alternative approaches of ‘treat all’, 
‘treat none’ or using a binary polypharmacy model to 
aid clinical decision making over a range of threshold 
probabilities of approximately 5%–40%.
discussion
The PRIME tool is the first validated tool to predict 
the absolute risk of an older person experiencing 
medication harm in the postdischarge period; the risk 
of MRH in this transition period is approximately 
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Figure 1 Prime tool to calculate patient risk of experiencing MRH requiring healthcare use within 8 weeks following hospital discharge. ADR, adverse 
drug reaction; GP, general practitioner; MRH, medication-related harm.
three times greater than the inpatient or ambulatory 
setting.2 15 33 57 Major strengths of the PRIME tool are 
that: (1) it was developed using multicentre prospec-
tive data identifying a robust outcome that has rele-
vance to patients, practitioners and policy makers (ie, 
definite MRH requiring healthcare use), (2) candidate 
predictors were clinically derived with patient and 
carer views considered, (3) the variables in the tool are 
routinely collected inpatient data, (4) the tool shows 
potentially superior clinical utility compared with 
some current risk stratification approaches based on a 
decision curve analysis.
This tool could support the WHO’s campaign to 
reduce MRH during transitions of care1 by flagging 
high-risk patients to target medicines optimisation 
interventions, and enabling clinicians to more accu-
rately evaluate the risks of polypharmacy for individual 
patients. Furthermore, the personalised information 
from the tool could inform more individualised discus-
sions around medication safety and enhance patient 
autonomy.58
comparison with other studies
There are no directly comparable MRH tools as this 
is the first developed for application to the transi-
tion of care following hospital discharge. Moreover, 
the PRIME tool calculates risk of MRH rather than 
solely ADR, as is the case with many existing tools 
(see online supplementary file for summary of existing 
tools). The PRIME tool’s discrimination and cali-
bration49 59 are comparable with these existing tools 
(PRIME C-statistic 0.66 vs C-statistics of other tools, 
eg, ADRROP60 (0.59), GerontoNet61 (0.70), PADR-
EC62 (0.67), BADRI63 (0.73), Trivalle64 (0.70)). The 
PRIME tool displayed good calibration, while other 
tools to predict MRH have not reported this impor-
tant measure, with exception of BADRI (Hosmer-Le-
meshow p=0.757, calibration plot not reported).23 63
The PRIME tool provides an absolute patient risk of 
MRH, whereas other tools indicate a relative patient 
risk based on scoring systems that round predictor 
ORs to the nearest integer. While there is merit in 
making a tool as simple as possible for routine clinical 
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Figure 2 Prime prediction tool compared with number of medicines alone to discriminate patient risk of medication harm. ROC, receiver operating 
characteristic.
Figure 3 Decision curve comparing the net benefit of alternative models for clinical decision making.
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use, it can lead to imprecision of calculating patient 
risk. Given the widespread use of electronic patient 
records in the hospital setting, there is no longer a 
need to compromise the precision of risk calculation 
to facilitate manual calculations.
The decision curve analysis shows that the PRIME 
tool offers a higher net benefit compared with existing 
strategies to target individuals at increased risk of 
MRH. For instance, the MedSafer17 randomised 
controlled deprescribing trial includes older patients 
using more than four regular medicines to determine 
if a deprescribing intervention reduces adverse drug 
events 30 days postdischarge. The PRIME tool could 
offer an improved approach to targeting higher risk 
individuals for such interventions.
Predictors in the model
The PRIME tool includes a combination of demo-
graphic (age, female gender), medication-specific 
(number of medicines, antiplatelet drug, antidiabetic 
drug, past ADR), biochemical (sodium level) and 
social predictors (living alone). This comprehensive 
set of patient information reflects the complexity of 
predicting MRH and healthcare use.65 We anticipated 
the tool to hold a high degree of face validity among 
both clinicians and patients given that the selection 
of candidate variables was informed by both. Most of 
the variables in the tool have been previously demon-
strated to be associated with MRH and/or unplanned 
healthcare utilisation in older adults.2 61 63 66–70 Few 
studies have investigated living alone as a risk factor 
for MRH.69 Our study substantiates self-reported 
evidence of adverse outcomes in older adults living 
alone following hospital discharge.71 The informal 
support from co-habiting family could facilitate medi-
cine adherence and promote early recognition and 
management of MRH.
Our study extends the pool of evidence for poor 
outcomes associated with low sodium levels, including 
the postdischarge setting.66 72–74 Even mild hypona-
traemia is associated with attention deficits, postural 
instability and falls.73 This might contribute to patients 
being less receptive to medicines information around 
discharge, and less able to tolerate common ADRs 
such as dizziness without serious consequences.
Over time, patterns of prescribing will change and 
ongoing updates and validation of the tool is recom-
mended,75 as has been the case for other tools.22 This 
might include investigating the impact of adding 
new prognostic factors, such as frailty76 and genetic 
variants.77
implications for practitioners and policy makers
The PRIME tool is unique in providing practitioners 
with a patient’s absolute risk of MRH following 
hospital discharge, and policy makers with a tool 
that identifies those that will consume healthcare 
resources as a consequence. While the tool has been 
developed to support a safer hospital discharge by 
better safeguarding patients at high risk of MRH, the 
variables in the PRIME tool are routinely available 
and its usefulness could be evaluated in primary care 
settings.
The absence thus far of an evidence-based mechanism 
to risk stratify patients could have contributed to the 
limited effectiveness of previously tested interventions 
to reduce MRH, in spite of strong face validity.17 78–81 
The PRIME tool could improve the efficiency and 
effectiveness of interventions to reduce MRH postdis-
charge.82 The integration of the tool into electronic 
discharge systems could automate the risk calculation 
and be made available to GPs on discharge summa-
ries. Furthermore, the visibility of patient MRH risk 
to doctors compiling discharge summaries may stim-
ulate wider positive changes in prescribing practices. 
For instance, it might prompt an additional check of 
the accuracy of the prescribed discharge medications 
given that a high proportion of discharge summaries 
convey inaccurate information of prescribed medi-
cines. The availability of MRH risk information to GPs 
could stimulate stronger consideration of whether new 
patient symptoms are due to disease or MRH. With 
the advent of Primary Care Networks in the NHS, 
through which a major focus is prescribing and medi-
cines safety, there is an opportunity to use the PRIME 
tool to prioritise the action of 7500 new clinical phar-
macists being introduced into general practice under 
NHS England’s £100 million medicines optimisation 
programme.83
The use of probabilities is an important part of 
conveying health risk to patients in a comprehen-
sible manner.84 85 Patients would co-own data on 
their risk of MRH at discharge, which might enhance 
their awareness that symptoms occurring in the initial 
weeks postdischarge might be due to MRH rather 
than the symptom of a new disease. Furthermore, the 
PRIME tool should aid better informed discussions 
between patients and doctors with regard to reducing 
polypharmacy, thus breaking down some barriers to 
deprescribing.86 Clinicians and patients tend to over-
estimate the benefits of treatments and underestimate 
the harms.87 88 Patients having individualised risk 
information could help to rebalance this skewed risk 
perception.
limitations
There are several limitations of this work to be consid-
ered. Research pharmacists identifying MRH were 
not blinded to the study aim, potentially introducing 
bias. In cases of MRH leading to hospital re-admis-
sion, consultants independent of the study assigned 
causality to the event alongside the research pharma-
cist, thereby reducing the impact of potential bias.
The PRIME tool was developed excluding patients 
with ‘possible’ and ‘probable’ MRH in order to 
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strengthen the reliability of the model to detect 
true MRH cases in real-world clinical practice. This 
hypothesis needs to be tested in an external valida-
tion phase. Although bootstrap is an optimal method 
for internally validating a prognostic tool, it is not 
a replacement for the necessary external validation 
phase prior to implementation. The usability of the 
tool, once implemented into an electronic system, 
will also require investigation. Nonetheless, the large 
cohort investigated in this study using a multicentre, 
prospective design, in conjunction with a robust 
approach to MRH verification, and adjustment for 
model optimism, lends the PRIME tool to favourable 
re-testing.
Although the PRIME tool’s C-statistic is not 
dissimilar to other tools for predicting complex 
outcomes, for example, stroke,89 certain cancers,90 
and hospital readmission,91 92 the implications of 
false positives and false negatives should be consid-
ered. While a false positive may result in increased 
medication scrutiny, the information on risk has 
potential to cause unnecessary concern to patients 
and clinicians. Additionally, any intervention will use 
clinical resource that might have been better placed 
elsewhere in the healthcare system. False negatives 
meanwhile limit the tool’s clinical utility to reduce 
MRH and avoidable healthcare use.
conclusions
The PRIME tool identifies older patients at high risk 
of MRH requiring healthcare use following hospital 
discharge. This could support efforts to target medi-
cines optimisation to reduce MRH and healthcare use. 
The tool should now be evaluated in new settings.
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